Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | USP14 | P54578 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713810 | 0.82 | PNMT (0.47) | PNMTCYP1A2KMT2ALMNACYP2C9 | |
| SCHEMBL6711082 | 0.79 | CYP1A2 (0.49) | CYP1A2KMT2ATSHRHSD17B10 | |
| SCHEMBL21822315 | 0.73 | CYP1A2 (0.34) | CYP1A2 | |
| SCHEMBL13540058 | 0.72 | GAA (0.41) | PNMTPDCD1CD274CYP1A2L3MBTL1 | |
| SCHEMBL22070895 | 0.71 | CYP11B1 (0.42) | CYP1A2L3MBTL1LMNAGRM5KDM4E | |
| SCHEMBL5765559 | 0.70 | MTNR1A (0.43) | CYP1A2KMT2ASMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL4020604 | 0.69 | CYP1A2 (0.56) | CYP1A2KMT2ASMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL11307625 | 0.69 | ITGB1 (0.55) | CYP1A2KMT2ASMN1; SMN2TSHRHSD17B10 | |
| SCHEMBL10532632 | 0.69 | PPARA (0.47) | PDCD1CD274CYP1A2GRM5 | |
| SCHEMBL13591312 | 0.68 | PPARA (0.42) | PDCD1CD274CYP1A2USP14GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-3860636-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | Disc Medicine, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-112996529-A | Matriptase 2 inhibitor and application thereof | 迪斯克医药公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020072580-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | PNMT 1345/4885PDCD1 4588/4885CD274 4856/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | PNMT 1345/4885PDCD1 4588/4885CD274 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.